Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: Results of the IMPACT-SHPT study

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 899-905

  Cozzolino, Mario ^a   Ketteler, Markus ^b   Martin, Kevin J ^c   Sharma, Amit ^d   Goldsmith, David ^e   Khan, Samina ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Nephrian   (United States)

^e GUY S HOSPITAL   (United Kingdom)

^f ABBVIE INC   (United States)

Author keywords

bone turnover marker; chronic kidney disease; cinacalcet; paricalcitol; secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; DOXERCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DISEASE; BONE MINERAL DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY ASSOCIATED SECONDARY HYPERPARATHYROIDISM; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE ASSOCIATED SECONDARY HYPERPARATHYROIDISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

BONE TURNOVER MARKER; CHRONIC KIDNEY DISEASE; CINACALCET; PARICALCITOL; SECONDARY HYPERPARATHYROIDISM;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84897387163     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu011     Document Type: Article

References (28)

1. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
2. United States Renal Data System (USRDS). CKD in the general population. In: USRDS. 2012 Atlas of CKD & ESRD. Volume 1. http://www.usrds.org/atlas. aspx (date last accessed, December 11, 2012
3. Grams ME, Coresh J. Assessing risk in chronic kidney disease: A methodological review. Nat Rev Nephrol 2013; 9: 18-25
4. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-Analysis. Lancet 2012; 380: 1662-1673
5. Lewis R. Mineral and bone disorders in chronic kidney disease: New insights into mechanism and management. Ann Clinical Biochem 2012; 49: 432-440
6. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
7. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67: 1576-1582
8. Mejía N, Roman-García P, Miar AB et al. Chronic kidney disease-mineral and bone disorder: A complex scenario. Nefrologia 2011; 31: 514-519
9. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
10. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
11. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
12. Drüeke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009; 4: 234-241
13. Martin KJ, González EA, Gellens M et al. 19-Nor-1-α-25- dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
14. Ketteler M, Martin KJ, Wolf M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 3270-3278
15. Ketteler M, Martin KJ, Cozzolino M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 1942-1949
16. National Kidney Foundation/KDOQI. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. New York, NY: National Kidney Foundation, Inc, 2003. http://www.kidney.org/professionals/KDOQI/ guidelines-commentaries.cfm (date last accessed, December 20, 2012
17. Ott SM. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 2008; 3(Suppl. 3): S151-S156
18. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885
19. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
20. Nitta K. Relationship between fibroblast growth factor-23 and mineral metabolism in chronic kidney disease. Int J Nephrol 2010; 2010: 167984
21. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27: 784-790
22. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
23. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125
24. Khan AM, Chirinos JA, Litt H et al. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012; 7: 2017-2022
25. Lee GH, Benner D, Regidor DL et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38-44
26. Tentori F, Hunt WC, Stidley CA et al. for the Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
27. Tonbul HZ, Solak Y, Atalay H et al. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail 2012; 34: 297-303
28. Hervás Sánchez JG, Prados Garrido MD, Polo Moyano A et al. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. Nefrologia 2011; 31: 697-706